High court picked Hikma’s ‘skinny label’ fight after letting the issue ‘percolate’
Hatch-Waxman & Biologics Chair Chad Landmon discusses how the Supreme Court’s decision on “skinny labels” could reshape how generic drugs come to market, and the legal risks involved.